Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H. Lundbeck ASFRA:LDBA -1.83%84 5-Year Yield-on-Cost % is 2.69 as of Jul. 14, 2026, which is 27% above its 10-year median of 2.12. GuruFocus rates FRA:LDBA with a GF Score™ of 84/100 and a GF Value™ of €6.21 (Fairly Valued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, H. Lundbeck AS ranks better than 58.91% on this metric.
H. Lundbeck AS's yield on cost for the quarter that ended in Mar. 2026 was 2.69.
The historical rank and industry rank for H. Lundbeck AS's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:LDBA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.55 Med: 2.12 Max: 3.96
Current: 2.69
During the past 13 years, H. Lundbeck AS's highest Yield on Cost was 3.96. The lowest was 1.55. And the median was 2.12.
FRA:LDBA's 5-Year Yield-on-Cost % is ranked better than 58.91% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.245
vs FRA:LDBA: 2.69
H. Lundbeck AS (FRA:LDBA) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
H. Lundbeck AS 5-Year Yield-on-Cost % Related Terms
FRA:LDBA vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of H. Lundbeck AS is calculated as
H. Lundbeck AS (FRA:LDBA) has a 5-Year Yield-on-Cost % of 2.69 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on H. Lundbeck AS and its competitors. This is 27% above median its historical median of 2.12. Over the past decade, H. Lundbeck AS's 5-Year Yield-on-Cost % has ranged from 1.55 to 3.96. According to the industry distribution chart, H. Lundbeck AS ranks #212 out of 516 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is H. Lundbeck AS's 5-Year Yield-on-Cost % too high?
H. Lundbeck AS's current 5-Year Yield-on-Cost % of 2.69 is 27% above median its 10-year median of 2.12. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 3.96. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. H. Lundbeck AS's value of 2.69 is 19.8% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #212 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #212 out of 516 companies for 5-Year Yield-on-Cost %. This puts H. Lundbeck AS in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. H. Lundbeck AS's value of 2.69 is 19.8% above this benchmark. Historically, H. Lundbeck AS's own 5-Year Yield-on-Cost % has ranged from 1.55 to 3.96 over the past decade. While the company's 10-year median is 2.12 vs. the industry median of 2.25, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current 5-Year Yield-on-Cost % of 2.69 is 19.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current 5-Year Yield-on-Cost % is 2.69, which is 27% above median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.21, compared to a current price of €5.63 — trading 9.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.69, which is 27% above median its 10-year median of 2.12 and 19.8% above the Drug Manufacturers industry median of 2.25. H. Lundbeck AS's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current 5-Year Yield-on-Cost % is 2.69 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.63 is trading 9.4% below its estimated GF Value™ of €6.21.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for FRA:LDBA:
5-Year Yield-on-Cost %: 2.69 (27% above median its 10-year median of 2.12)
GF Value™: €6.21 vs. price of €5.63 (9.4% below fair value)
Industry Position: 19.8% above the Drug Manufacturers median (#212 of 516)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
84GF Score
Get the complete analysis for FRA:LDBA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
